Image Based Cytometry in Cell Analysis Market

Image Based Cytometry in Cell Analysis Market (End-user: Biotechnology & Pharmaceutical Companies, Academia, Cosmetic Industry, Contract Research Organizations, and Contract Development & Manufacturing Organizations) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Global Image-based Cytometry in Cell Analysis Market Outlook 2031

  • The global industry was valued at US$ 2.7 Bn in 2022
  • It is projected to advance at a CAGR of 10.4% from 2023 to 2031 and reach more than US$ 6.5 Bn by the end of 2031

Analysts’ Viewpoint

Growth in clinical trials, technological advancement in image-based cytometry, and increase in partnerships & M&A activities are fueling global image-based cytometry in cell analysis market growth. Rise in adoption of image-based cytometry for drug discovery and development is also driving market expansion. Furthermore, rise in spending capacity of end-users, high prevalence of chronic diseases, and improved healthcare infrastructure in emerging economies are creating significant image-based cytometry in cell analysis market opportunities.

High cost of instruments and limited availability of skilled labors are expected to hamper market statistics during the forecast period. Manufacturers and service providers in the image-based cytometry in cell analysis market are focusing on developing products and services that are tailored to the needs and budget constraints of emerging markets.

Image Based Cytometry In Cell Analysis Market

Global Image-based Cytometry in Cell Analysis Market Overview

Image-based cytometry in cell analysis is a cutting-edge technology used in biological research and clinical diagnostics to analyze cells and cellular processes. It combines the principles of flow cytometry and microscopy with advanced image analysis algorithms, enabling researchers to obtain detailed information about cell populations and their characteristics.

Traditionally, flow cytometry has been the gold standard for cell analysis, allowing the detection and quantification of multiple cellular parameters simultaneously. However, it has limitations when it comes to visualizing cellular morphology and spatial relationships. Imaging flow cytometry overcomes these limitations by capturing high-resolution images of cells and analyzing them using sophisticated image analysis software.

Increase in Number of M&A Activities and Partnerships

Companies are increasing their market share by implementing various strategies such as new product development, acquisitions, employing effective advertising, and pricing products and services efficiently. For instance, in February 2023, Cytek Biosciences, Inc. and DiaSorin announced that Cytek would acquire the Flow Cytometry & Imaging (FCI) business unit from Luminex Corporation, a DiaSorin subsidiary. This acquisition would broaden Cytek's global commercial footprint by incorporating an existing installed base of over 7000 instruments.

In January 2022, Becton, Dickinson and Company collaborated with the European Molecular Biology Laboratory (EMBL) to evaluate the potential of flow cytometry with imaging technology in transforming immunology, cell biology, and genomics research and enabling new cell-based therapeutic discovery.

In May 2023, Becton, Dickinson and Company launched a new cell sorting instrument, BD FACSDiscover S8 Cell Sorter, globally. This instrument is the first in the world to combine two breakthrough technologies, namely spectral flow cytometry and real-time imaging technology. This new instrument offers researchers an unprecedented level of insight into cell behavior and function, and has the potential to transform the field of cell research.

These strategies help companies attain a sustained competitive advantage over their competitors.

Rise in Purchasing Power of End-users in Emerging Economies

Improvement in end-users' purchasing power in emerging economies is a crucial opportunity for players operating in the image-based cytometry in cell analysis market. Rise in purchasing power increases the spending capacity of end-users and enables them to invest in high-cost instruments.

Emerging markets in Asia, Africa, and Latin America are experiencing rapid economic development owing to increase in investment in research & development, healthcare, and biotechnology.

In November 2022, Visiopharm and Standard BioTools announced a partnership to develop complete image analysis solutions that would be packaged with the Hyperion and Hyperion+ Imaging Systems. Hyperion and Hyperion+ Imaging Systems are advanced imaging platforms that enable high-resolution imaging of cells and tissues, providing researchers with a powerful tool for investigating complex biological systems.

Surge in Adoption of Image-based Cytometry by Biotechnology & Pharmaceutical Companies

In terms of end-user, the global market has been segmented into biotechnology & pharmaceutical companies, academia, cosmetic industry, contract research organizations, and contract development & manufacturing organizations. As per the image-based cytometry in cell analysis industry research report, the biotechnology & pharmaceutical companies segment is projected to lead the global market in the near future.

Technological advancement in image-based cytometry enables biotechnology & pharmaceutical companies to analyze large datasets and extract meaningful insights from complex cellular images and assist them in drug development. Image-based cytometry technology can be integrated with other advanced technologies, such as artificial intelligence and high-content imaging cytometry, to increase the scope of applications in several biotechnology & pharmaceutical companies.

Increase in Application of Image-based Cytometry in Cell Analysis in Oncology & Immune-oncology

Based on therapeutic area, the oncology & immune-oncology segment is estimated to dominate the global market during the forecast period.

The oncology & immune-oncology segment can be further classified into small molecules, protein-based therapeutics, cell therapy, and nucleic acid-based drugs. The nucleic acid-based drugs sub-segment is anticipated to expand at a high CAGR from 2023 to 2031.

Reliable and precise methods for detecting cancer and categorizing patients are fundamental in modern oncology. In clinical practice, various techniques are employed to obtain cancer specimens. Recent advancements in engineering and advanced AI have led to the development of a new generation of image cytometers that can operate effectively with minimal biological material.

Image cytometers offer quantitative and qualitative information about cancer cells and their characteristics. They aid in accurate diagnosis, prognostic assessment, treatment monitoring, and research, ultimately contributing to improved patient care and outcomes in the field of oncology. Hence, image-based cytometry in cell analysis market demand is expected to rise in the near future due to the increase in cases of cancers.

Regional Outlook of Global Image-based Cytometry in Cell Analysis Industry

The U.S. accounted for major image-based cytometry in cell analysis market share in 2022. According to the latest image-based cytometry in cell analysis market forecast, the U.S. is projected to dominate the global industry during the forecast period.

Rise in number of genomic screening projects and increase in demand for cell-based diagnostics and characterization of cells in healthy and diseased states are the key factors contributing to the market progress in the U.S.

The market in China is anticipated to grow at a rapid pace during the forecast period. Increase in adoption of image-based cytometry technology among various players and researchers in China is fueling market development. Market players in China are also exploring opportunities in personalized therapies.

Analysis of Key Players

The global landscape is fragmented, with the presence of several manufacturers. Key players operating in the market are PerkinElmer, Inc., Merck KGaA, Sartorius AG, Thermo Fisher Scientific, Inc., Carl Zeiss Meditec AG, Charles River Laboratories, Yokogawa Electric Corporation, and Nanolive SA. These players are following the trends in image-based cytometry technologies to avail lucrative revenue opportunities.

Key Developments in Global Image-based Cytometry in Cell Analysis Market

  • In September 2022, PerkinElmer, Inc. introduced the Cellaca PLX Image Cytometry System, a pioneering benchtop platform designed to allow researchers to evaluate numerous Critical Quality Attributes (CQAs) of cell samples in a single automated workflow. Researchers can assess factors such as cell identity, quality, and quantity, all in one go, using this system.
  • In November 2021, Merck KGaA unveiled its ColorWheel flow cytometry portfolio, which utilizes a proprietary technology optimized for flow cytometry. This technology enables users to independently select dyes and antibodies and combine them in any desired configuration. The resulting output is comparable to that of a primary conjugated antibody. The ColorWheel portfolio addresses the challenges faced by researchers while performing multiplexing in flow cytometry, including balancing antigen expression with dye brightness, ensuring the availability of specific antibody-dye combinations, and configuring the instrument.

Prominent players in the image-based cytometry in cell analysis market report have been profiled based on parameters such as product portfolio, latest developments, company overview, business strategies, business segments, and financial overview.

Global Image-based Cytometry in Cell Analysis Market Snapshot

Attribute Detail
Size in 2022 US$ 2.7 Bn
Forecast (Value) in 2031 More than US$ 6.5 Bn
Growth Rate (CAGR) 10.4%
Forecast Period 2023-2031
Historical Data Available for 2017-2022
Quantitative Units US$ Bn for Value
Market Analysis It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, and opportunities.
Competition Landscape
  • Market share analysis by company (2022)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format Electronic (PDF) + Excel
Segmentation
  • End-user
    • Biotechnology & Pharmaceutical Companies
    • Therapeutic Area
      • Oncology & Immune-oncology
        • Small Molecules
        • Protein-based Therapeutics
        • Cell Therapy
        • Nucleic Acid-based Drugs
      • Cardiovascular & Metabolic Diseases
        • Small Molecules
        • Protein-based
        • Therapeutics
        • Cell Therapy
        • Nucleic Acid-based Drugs
      • Immunology
        • Small Molecules
        • Protein-based Therapeutics
        • Cell Therapy
        • Nucleic Acid-based Drugs
      • Rare Diseases
        • Small Molecules
        • Protein-based Therapeutics
        • Cell Therapy
        • Nucleic Acid-based Drugs
      • Neurological Diseases
        • Small Molecules
        • Protein-based Therapeutics
        • Cell Therapy
        • Nucleic Acid-based Drugs
      • Others
        • Small Molecules
        • Protein-based Therapeutics
        • Cell Therapy
        • Nucleic Acid-based Drugs
    • Workplace
      • Target Identification
      • Hit Generation & Lead Identification
      • Lead Optimization
      • In Vitro Preclinical Studies
      • In Vivo Preclinical Studies
      • Clinical Studies
    • Academia
    • Cosmetic Industry
    • Contract Research Organizations
    • Contract Development & Manufacturing Organizations
Regions/Countries Covered
  • U.S.
  • Europe
  • China
  • Rest of the World
Companies Profiled
  • PerkinElmer, Inc.
  • Merck KGaA
  • Sartorius AG
  • Thermo Fisher Scientific, Inc.
  • Carl Zeiss Meditec AG
  • Charles River Laboratories
  • Yokogawa Electric Corporation
  • Nanolive SA
Customization Scope Available upon request
Pricing Available upon request

Frequently Asked Questions

How big was the global image based cytometry in cell analysis market in 2022?

It was valued at US$ 2.7 Bn in 2022

How big will be the image based cytometry in cell analysis business in 2031?

It is anticipated to reach more than US$ 6.5 Bn by 2031

What will be the CAGR of the image based cytometry in cell analysis industry during the forecast period (2023-2031)?

The CAGR is projected to be 10.4% during the forecast period

Which are the major factors driving demand for image based cytometry in cell analysis?

Increase in number of clinical trials and technological advancements in image-based cytometry

Which image based cytometry in cell analysis segment accounted for major share in 2022?

The biotechnology & pharmaceutical companies end-user segment held major share of over 50.0% in 2022

How is the demand for image-based cytometry in cell analysis in the U.S.?

Demand for image based cytometry in cell analysis is likely to rise in the country during the forecast period

Who are the prominent companies in the image based cytometry in cell analysis sector?

PerkinElmer, Inc., Merck KGaA, Sartorius AG, Thermo Fisher Scientific, Inc., Carl Zeiss Meditec AG, Charles River Laboratories, Yokogawa Electric Corporation, and Nanolive SA

    1. Preface

        1.1. Market Definition and Scope

        1.2. Key Research Objectives

    2. Assumptions and Research Methodology

    3. Market Overview

        3.1. Overview

        3.2. Market Dynamics

            3.2.1. Drivers

            3.2.2. Restraints

            3.2.3. Opportunities

    4. Global Image-based Cytometry in Cell Analysis Market Analysis and Forecast, by End-user

        4.1. Introduction & Definition

        4.2. Key Findings/Developments

        4.3. Market Value Forecast, by End-user, 2017-2031

            4.3.1. Biotechnology & Pharmaceutical Companies

            4.3.2. Academia

            4.3.3. Cosmetic Industry

            4.3.4. Contract Research Organizations

            4.3.5. Contract Development & Manufacturing Organizations

    5. Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Analysis and Forecast, by Therapeutic Area

        5.1. Introduction & Definition

        5.2. Key Findings/Developments

        5.3. Market Value Forecast, by Therapeutic Area, 2015-2031

            5.3.1. Oncology & Immune-oncology

                5.3.1.1. Small Molecules

                5.3.1.2. Protein-based Therapeutics

                5.3.1.3. Cell Therapy

                5.3.1.4. Nucleic Acid-based Drugs

            5.3.2. Cardiovascular & Metabolic Diseases

                5.3.2.1. Small Molecules

                5.3.2.2. Protein-based Therapeutics

                5.3.2.3. Cell Therapy

                5.3.2.4. Nucleic Acid-based Drugs

            5.3.3. Immunology

                5.3.3.1. Small Molecules

                5.3.3.2. Protein-based Therapeutics

                5.3.3.3. Cell Therapy

                5.3.3.4. Nucleic Acid-based Drugs

            5.3.4. Rare Diseases

                5.3.4.1. Small Molecules

                5.3.4.2. Protein-based Therapeutics

                5.3.4.3. Cell Therapy

                5.3.4.4. Nucleic Acid-based Drugs

            5.3.5. Neurological Diseases

                5.3.5.1. Small Molecules

                5.3.5.2. Protein-based Therapeutics

                5.3.5.3. Cell Therapy

                5.3.5.4. Nucleic Acid-based Drugs

            5.3.6. Others

                5.3.6.1. Small Molecules

                5.3.6.2. Protein-based Therapeutics

                5.3.6.3. Cell Therapy

                5.3.6.4. Nucleic Acid-based Drugs

    6. Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Analysis and Forecast, by Workplace

        6.1. Introduction & Definition

        6.2. Key Findings/Developments

        6.3. Market Value Forecast, by Workplace, 2016-2031

            6.3.1. Target Identification

            6.3.2. Hit Generation & Lead Identification

            6.3.3. Lead Optimization

            6.3.4. In Vitro Preclinical Studies

            6.3.5. In Vivo Preclinical Studies

            6.3.6. Clinical Studies

    7. Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Analysis and Forecast, by Country/Region

        7.1. Key Findings

        7.2. Market Value Forecast, by Country/Region, 2017-2031

            7.2.1. U.S.

            7.2.2. Europe

            7.2.3. China

            7.2.4. Rest of the World

    8. U.S. Image-based Cytometry in Cell Analysis Market Analysis and Forecast

        8.1. Introduction

            8.1.1. Key Findings

        8.2. Market Value Forecast, by End-user, 2017-2031

            8.2.1. Biotechnology & Pharmaceutical Companies

            8.2.2. Academia

            8.2.3. Cosmetic Industry

            8.2.4. Contract Research Organizations

            8.2.5. Contract Development & Manufacturing Organizations

        8.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031

            8.3.1. Oncology & Immune-oncology

                8.3.1.1. Small Molecules

                8.3.1.2. Protein-based Therapeutics

                8.3.1.3. Cell Therapy

                8.3.1.4. Nucleic Acid-based Drugs

            8.3.2. Cardiovascular & Metabolic Diseases

                8.3.2.1. Small Molecules

                8.3.2.2. Protein-based Therapeutics

                8.3.2.3. Cell Therapy

                8.3.2.4. Nucleic Acid-based Drugs

            8.3.3. Immunology

                8.3.3.1. Small Molecules

                8.3.3.2. Protein-based Therapeutics

                8.3.3.3. Cell Therapy

                8.3.3.4. Nucleic Acid-based Drugs

            8.3.4. Rare Diseases

                8.3.4.1. Small Molecules

                8.3.4.2. Protein-based Therapeutics

                8.3.4.3. Cell Therapy

                8.3.4.4. Nucleic Acid-based Drugs

            8.3.5. Neurological Diseases

                8.3.5.1. Small Molecules

                8.3.5.2. Protein-based Therapeutics

                8.3.5.3. Cell Therapy

                8.3.5.4. Nucleic Acid-based Drugs

            8.3.6. Others

                8.3.6.1. Small Molecules

                8.3.6.2. Protein-based Therapeutics

                8.3.6.3. Cell Therapy

                8.3.6.4. Nucleic Acid-based Drugs

        8.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031

            8.4.1. Target Identification

            8.4.2. Hit Generation & Lead Identification

            8.4.3. Lead Optimization

            8.4.4. In Vitro Preclinical Studies

            8.4.5. In Vivo Preclinical Studies

            8.4.6. Clinical Studies

    9. Europe Image-based Cytometry in Cell Analysis Market Analysis and Forecast

        9.1. Introduction

            9.1.1. Key Findings

        9.2. Market Value Forecast, by End-user, 2017-2031

            9.2.1. Biotechnology & Pharmaceutical Companies

            9.2.2. Academia

            9.2.3. Cosmetic Industry

            9.2.4. Contract Research Organizations

            9.2.5. Contract Development & Manufacturing Organizations

        9.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031

            9.3.1. Oncology & Immune-oncology

                9.3.1.1. Small Molecules

                9.3.1.2. Protein-based Therapeutics

                9.3.1.3. Cell Therapy

                9.3.1.4. Nucleic Acid-based Drugs

            9.3.2. Cardiovascular & Metabolic Diseases

                9.3.2.1. Small Molecules

                9.3.2.2. Protein-based Therapeutics

                9.3.2.3. Cell Therapy

                9.3.2.4. Nucleic Acid-based Drugs

            9.3.3. Immunology

                9.3.3.1. Small Molecules

                9.3.3.2. Protein-based Therapeutics

                9.3.3.3. Cell Therapy

                9.3.3.4. Nucleic Acid-based Drugs

            9.3.4. Rare Diseases

                9.3.4.1. Small Molecules

                9.3.4.2. Protein-based Therapeutics

                9.3.4.3. Cell Therapy

                9.3.4.4. Nucleic Acid-based Drugs

            9.3.5. Neurological Diseases

                9.3.5.1. Small Molecules

                9.3.5.2. Protein-based Therapeutics

                9.3.5.3. Cell Therapy

                9.3.5.4. Nucleic Acid-based Drugs

            9.3.6. Others

                9.3.6.1. Small Molecules

                9.3.6.2. Protein-based Therapeutics

                9.3.6.3. Cell Therapy

                9.3.6.4. Nucleic Acid-based Drugs

        9.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031

            9.4.1. Target Identification

            9.4.2. Hit Generation & Lead Identification

            9.4.3. Lead Optimization

            9.4.4. In Vitro Preclinical Studies

            9.4.5. In Vivo Preclinical Studies

            9.4.6. Clinical Studies

        9.5. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Country/Sub-region, 2017-2031

            9.5.1. EU5

            9.5.2. U.K.

            9.5.3. Switzerland

            9.5.4. Rest of Europe

    10. China Image-based Cytometry in Cell Analysis Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast, by End-user, 2017-2031

            10.2.1. Biotechnology & Pharmaceutical Companies

            10.2.2. Academia

            10.2.3. Cosmetic Industry

            10.2.4. Contract Research Organizations

            10.2.5. Contract Development & Manufacturing Organizations

        10.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031

            10.3.1. Oncology & Immune-oncology

                10.3.1.1. Small Molecules

                10.3.1.2. Protein-based Therapeutics

                10.3.1.3. Cell Therapy

                10.3.1.4. Nucleic Acid-based Drugs

            10.3.2. Cardiovascular & Metabolic Diseases

                10.3.2.1. Small Molecules

                10.3.2.2. Protein-based Therapeutics

                10.3.2.3. Cell Therapy

                10.3.2.4. Nucleic Acid-based Drugs

            10.3.3. Immunology

                10.3.3.1. Small Molecules

                10.3.3.2. Protein-based Therapeutics

                10.3.3.3. Cell Therapy

                10.3.3.4. Nucleic Acid-based Drugs

                10.3.3.5. Nucleic Acid

            10.3.4. Rare Diseases

                10.3.4.1. Small Molecules

                10.3.4.2. Protein-based Therapeutics

                10.3.4.3. Cell Therapy

                10.3.4.4. Nucleic Acid-based Drugs

            10.3.5. Neurological Diseases

                10.3.5.1. Small Molecules

                10.3.5.2. Protein-based Therapeutics

                10.3.5.3. Cell Therapy

                10.3.5.4. Nucleic Acid-based Drugs

            10.3.6. Others

                10.3.6.1. Small Molecules

                10.3.6.2. Protein-based Therapeutics

                10.3.6.3. Cell Therapy

                10.3.6.4. Nucleic Acid-based Drugs

        10.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031

            10.4.1. Target Identification

            10.4.2. Hit Generation & Lead Identification

            10.4.3. Lead Optimization

            10.4.4. In Vitro Preclinical Studies

            10.4.5. In Vivo Preclinical Studies

            10.4.6. Clinical Studies

    11. Rest of the World Image-based Cytometry in Cell Analysis Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by End-user, 2017-2031

            11.2.1. Biotechnology & Pharmaceutical Companies

            11.2.2. Academia

            11.2.3. Cosmetic Industry

            11.2.4. Contract Research Organizations

            11.2.5. Contract Development & Manufacturing Organizations

        11.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031

            11.3.1. Oncology & Immune-oncology

                11.3.1.1. Small Molecules

                11.3.1.2. Protein-based Therapeutics

                11.3.1.3. Cell Therapy

                11.3.1.4. Nucleic Acid-based Drugs

            11.3.2. Cardiovascular & Metabolic Diseases

                11.3.2.1. Small Molecules

                11.3.2.2. Protein-based Therapeutics

                11.3.2.3. Cell Therapy

                11.3.2.4. Nucleic Acid-based Drugs

            11.3.3. Immunology

                11.3.3.1. Small Molecules

                11.3.3.2. Protein-based Therapeutics

                11.3.3.3. Cell Therapy

                11.3.3.4. Nucleic Acid-based Drugs

            11.3.4. Rare Diseases

                11.3.4.1. Small Molecules

                11.3.4.2. Protein-based Therapeutics

                11.3.4.3. Cell Therapy

                11.3.4.4. Nucleic Acid-based Drugs

            11.3.5. Neurological Diseases

                11.3.5.1. Small Molecules

                11.3.5.2. Protein-based Therapeutics

                11.3.5.3. Cell Therapy

                11.3.5.4. Nucleic Acid-based Drugs

            11.3.6. Others

                11.3.6.1. Small Molecules

                11.3.6.2. Protein-based Therapeutics

                11.3.6.3. Cell Therapy

                11.3.6.4. Nucleic Acid-based Drugs

        11.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031

            11.4.1. Target Identification

            11.4.2. Hit Generation & Lead Identification

            11.4.3. Lead Optimization

            11.4.4. In Vitro Preclinical Studies

            11.4.5. In Vivo Preclinical Studies

            11.4.6. Clinical Studies

    12. Competition Landscape

        12.1. Market Share Analysis, by Company (2022)

        12.2. Company Profiles

            12.2.1. Nanolive SA

                12.2.1.1. Company Overview

                12.2.1.2. Product Portfolio/Brands with its Description/Features

                12.2.1.3. Strategic Overview/Recent Developments

                12.2.1.4. SWOT Analysis

            12.2.2. PerkinElmer, Inc.

                12.2.2.1. Company Overview

                12.2.2.2. Product Portfolio/Brands with its Description/Features

                12.2.2.3. Financial Overview

                12.2.2.4. Strategic Overview/Recent Developments

                12.2.2.5. SWOT Analysis

            12.2.3. Sartorius AG

                12.2.3.1. Company Overview

                12.2.3.2. Product Portfolio/Brands with its Description/Features

                12.2.3.3. Financial Overview

                12.2.3.4. Strategic Overview/Recent Developments

                12.2.3.5. SWOT Analysis

            12.2.4. Thermo Fisher Scientific Inc.

                12.2.4.1. Company Overview

                12.2.4.2. Product Portfolio/Brands with its Description/Features

                12.2.4.3. Financial Overview

                12.2.4.4. Strategic Overview/Recent Developments

                12.2.4.5. SWOT Analysis

            12.2.5. Merck KGaA

                12.2.5.1. Company Overview

                12.2.5.2. Product Portfolio/Brands with its Description/Features

                12.2.5.3. Financial Overview

                12.2.5.4. Strategic Overview/Recent Developments

                12.2.5.5. SWOT Analysis

            12.2.6. Charles River Laboratories

                12.2.6.1. Company Overview

                12.2.6.2. Product Portfolio/Brands with its Description/Features

                12.2.6.3. Financial Overview

                12.2.6.4. SWOT Analysis

            12.2.7. Yokogawa Electric Corporation

                12.2.7.1. Company Overview

                12.2.7.2. Product Portfolio/Brands with its Description/Features

                12.2.7.3. Financial Overview

                12.2.7.4. SWOT Analysis

            12.2.8. Carl Zeiss AG

                12.2.8.1. Company Overview

                12.2.8.2. Product Portfolio/Brands with its Description/Features

                12.2.8.3. Financial Overview

                12.2.8.4. Strategic Overview/Recent Developments

                12.2.8.5. SWOT Analysis

    List of Tables

    Table 01: Global Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by End-user, 2017-2031

    Table 02: Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031

    Table 03: Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Oncology & Immune-oncology, 2017-2031

    Table 04: Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Cardiovascular & Metabolic Diseases, 2017-2031

    Table 05: Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Immunology, 2017-2031

    Table 06: Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Rare Diseases, 2017-2031

    Table 07: Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Neurological Diseases, 2017-2031

    Table 08: Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Others, 2017-2031

    Table 09: Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Workplace, 2017-2031

    Table 10: Global Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Region, 2017-2031

    Table 11: U.S. Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by End-user, 2017-2031

    Table 12: U.S. Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031

    Table 13: U.S. Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Oncology & Immune-oncology, 2017-2031

    Table 14: U.S. Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Cardiovascular & Metabolic Diseases, 2017-2031

    Table 15: U.S. Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Immunology, 2017-2031

    Table 16: U.S. Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Rare Diseases, 2017-2031

    Table 17: U.S. Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Neurological Diseases, 2017-2031

    Table 18: U.S. Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Others, 2017-2031

    Table 19: U.S. Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Workplace, 2017-2031

    Table 20: Europe Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by End-user, 2017-2031

    Table 21: Europe Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031

    Table 22: Europe Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Oncology & Immune-oncology, 2017-2031

    Table 23: Europe Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Cardiovascular & Metabolic Diseases, 2017-2031

    Table 24: Europe Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Immunology, 2017-2031

    Table 25: Europe Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Rare Diseases, 2017-2031

    Table 26: Europe Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Neurological Diseases, 2017-2031

    Table 27: Europe Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Others, 2017-2031

    Table 28: Europe Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Workplace, 2017-2031

    Table 29: Europe Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 30: China Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by End-user, 2017-2031

    Table 31: China Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031

    Table 32: China Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Oncology & Immune-oncology, 2017-2031

    Table 33: China Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Cardiovascular & Metabolic Diseases, 2017-2031

    Table 34: China Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Immunology, 2017-2031

    Table 35: China Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Rare Diseases, 2017-2031

    Table 36: China Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Neurological Diseases, 2017-2031

    Table 37: China Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Others, 2017-2031

    Table 38: China Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Workplace, 2017-2031

    Table 39: Rest of the World Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by End-user, 2017-2031

    Table 40: Rest of the World Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031

    Table 41: China Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Oncology & Immune-oncology, 2017-2031

    Table 42: Rest of the World Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Cardiovascular & Metabolic Diseases, 2017-2031

    Table 43: Rest of the World Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Immunology, 2017-2031

    Table 44: Rest of the World Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Rare Diseases, 2017-2031

    Table 45: Rest of the World Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Neurological Diseases, 2017-2031

    Table 46: Rest of the World Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Others, 2017-2031

    Table 47: Rest of the World Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Workplace, 2017-2031

    List of Figures

    Figure 01: Growth in Adoption of CyTOF in National Clinical Trials

    Figure 02: National Clinical Trials Citing CyTOF Technology, by Research Area, 2022

    Figure 03: Number of Clinical Trials, by Platform, 2022

    Figure 04: Global Image-based Cytometry in Cell Analysis Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 05: Global Image-based Cytometry in Cell Analysis Market Attractiveness Analysis, by End-user, 2023-2031

    Figure 06: Global Image-based Cytometry in Cell Analysis Market (US$ Mn), by Biotechnology & Pharmaceutical Companies, 2017-2031

    Figure 07: Global Image-based Cytometry in Cell Analysis Market (US$ Mn), by Academia, 2017-2031

    Figure 08: Global Image-based Cytometry in Cell Analysis Market (US$ Mn), by Cosmetic Industry, 2017-2031

    Figure 09: Global Image-based Cytometry in Cell Analysis Market (US$ Mn), by Contract Research Organizations, 2017-2031

    Figure 10: Global Image-based Cytometry in Cell Analysis Market (US$ Mn), by Contract Development & Manufacturing Organizations, 2017-2031

    Figure 11: Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value Share Analysis, by Therapeutic Area, 2022 and 2031

    Figure 12: Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Attractiveness Analysis, by Therapeutic Area, 2023-2031

    Figure 13: Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market (US$ Mn), by Oncology & Immune-oncology, 2017-2031

    Figure 14: Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market (US$ Mn), by Cardiovascular & Metabolic Diseases, 2017-2031

    Figure 15: Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market (US$ Mn), by Immunology, 2017-2031

    Figure 16: Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market (US$ Mn), by Rare Diseases, 2017-2031

    Figure 17: Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market (US$ Mn), by Neurological Diseases, 2017-2031

    Figure 18: Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market (US$ Mn), by Others, 2017-2031

    Figure 19: Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Analysis and Forecast, by Workplace, 2022 and 2031

    Figure 20: Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Attractiveness Analysis, by Workplace, 2023-2031

    Figure 21: Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market (US$ Mn), by Target Identification, 2017-2031

    Figure 22: Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market (US$ Mn), by Hit Generation & Lead Identification, 2017-2031

    Figure 23: Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market (US$ Mn), by Lead Optimization, 2017-2031

    Figure 24: Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market (US$ Mn), by In Vitro Preclinical Studies, 2017-2031

    Figure 25: Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market (US$ Mn), by In Vivo Preclinical Studies, 2017-2031

    Figure 26: Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market (US$ Mn), by Clinical Studies, 2017-2031

    Figure 27: Global Image-based Cytometry in Cell Analysis Market Value Share Analysis, by Region, 2022 and 2031

    Figure 28: Global Image-based Cytometry in Cell Analysis Market Attractiveness Analysis, by Region, 2023-2031

    Figure 29: U.S. Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, 2017-2031

    Figure 30: U.S. Image-based Cytometry in Cell Analysis Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 31: U.S. Image-based Cytometry in Cell Analysis Market Attractiveness Analysis, by End-user, 2023-2031

    Figure 32: U.S. Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value Share Analysis, by Therapeutic Area, 2022 and 2031

    Figure 33: U.S. Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Attractiveness Analysis, by Therapeutic Area, 2023-2031

    Figure 34: U.S. Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value Share Analysis, by Workplace, 2022 and 2031

    Figure 35: U.S. Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Attractiveness Analysis, by Workplace, 2023-2031

    Figure 36: Europe Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, 2017-2031

    Figure 37: Europe Image-based Cytometry in Cell Analysis Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 38: Europe Image-based Cytometry in Cell Analysis Market Attractiveness Analysis, by End-user, 2023-2031

    Figure 39: Europe Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value Share Analysis, by Therapeutic Area, 2022 and 2031

    Figure 40: Europe Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Attractiveness Analysis, by Therapeutic Area, 2023-2031

    Figure 41: Europe Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value Share Analysis, by Workplace, 2022 and 2031

    Figure 42: Europe Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Attractiveness Analysis, by Workplace, 2023-2031

    Figure 43: Europe Image-based Cytometry in Cell Analysis Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 44: Europe Image-based Cytometry in Cell Analysis Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 45: China Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, 2017-2031

    Figure 46: China Image-based Cytometry in Cell Analysis Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 47: China Image-based Cytometry in Cell Analysis Market Attractiveness Analysis, by End-user, 2023-2031

    Figure 48: China Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value Share Analysis, by Therapeutic Area, 2022 and 2031

    Figure 49: China Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Attractiveness Analysis, by Therapeutic Area, 2023-2031

    Figure 50: China Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value Share Analysis, by Workplace, 2022 and 2031

    Figure 51: China Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Attractiveness Analysis, by Workplace, 2023-2031

    Figure 52: Rest of the World Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, 2017-2031

    Figure 53: Rest of the World Image-based Cytometry in Cell Analysis Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 54: Rest of the World Image-based Cytometry in Cell Analysis Market Attractiveness Analysis, by End-user, 2023-2031

    Figure 55: Rest of the World Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value Share Analysis, by Therapeutic Area, 2022 and 2031

    Figure 56: Rest of the World Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Attractiveness Analysis, by Therapeutic Area, 2023-2031

    Figure 57: Rest of the World Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value Share Analysis, by Workplace, 2022 and 2031

    Figure 58: Rest of the World Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Attractiveness Analysis, by Workplace, 2023-2031

    Figure 59: Global Image-based Cytometry in Cell Analysis Market Share Analysis, by Company, 2022

Copyright © Transparency Market Research, Inc. All Rights reserved